01 — At a Glance
Medanta’s Epic Growth Story Has Two Sides. One’s Shiny. One’s Bleeding.
- 52-Week High / Low₹1,456 / ₹1,010
- Q3 Revenue₹1,121 Cr
- Q3 PAT (as reported)₹95 Cr
- Q3 EBITDA (ex-Noida)₹2,814 Cr
- Annualised EPS (Q3×4)₹14.16
- Book Value₹138
- Price to Book7.90x
- Dividend Yield0.05%
- Debt / Equity0.25x
- CRISIL Rating (Dec 2025)AA/Stable
The Setup: Global Health (Medanta hospitals) just reported Q3 FY26 revenue of ₹1,121 crore, up 18.8% YoY. But here’s the twist — PAT came in at only ₹95 crore (down 13.2% YoY) because Noida, their fancy new 550-bed hospital, bled ₹320 crore in EBITDA losses in its first full quarter of operations. Adjust for a one-time labour code item (₹366 cr statutory hit), and adjusted PAT would have been ₹1,224 crore. The stock is trading at 51.7x trailing P/E. That’s not a valuation. That’s a faith statement.
02 — Introduction
Healthcare’s Sharpest Surgeon Trying to Build the Next Hospital Empire
Global Health Limited operates under the “Medanta” brand — a word that means “healer” in Sanskrit and also happens to be the billing statement your wallet sees after any visit.
Founded by Dr Naresh Trehan (a cardiac surgeon with legitimate credentials, not just a hospital influencer), Medanta has established itself as India’s leading tertiary care provider in the NCR, East, and Central regions. Six hospitals today. 3,435 beds as of September 2025. Plans for 5,000 beds by 2027. An empire being built on volumes, specialization, and capital deployment that would make most PE firms blush.
The story is intoxicating: double-digit revenue growth, expanding margins in mature hospitals (Gurgaon running at 23.9% EBITDA margins), new hospitals ramping at 30%+ margins, and CRISIL just upgraded the company’s debt rating to AA/Stable in December 2025 — a vote of confidence in the execution machine. But Noida’s ₹320-crore quarterly loss is the problem no analyst presentation can soft-pedal. That’s not a “ramp-up cost.” That’s a validation that greenfield hospitals burn cash like airport lounges burn WiFi passwords.
So let’s break it down: the revenue growth is real. The margin story is compelling. But at 51.7x P/E, is this the stock of a world-class operator, or the market’s romantic notion of one?
Concall Insight (Feb 2026): Management said they’re “hopeful” Q3 was the peak loss for Noida, citing clinician build near completion and revenue run-rates improving. But they explicitly avoided giving a breakeven timeline. Translation: even they don’t know exactly when Noida will turn. Caution is warranted.
03 — Business Model: Making Hospitals Run Like IPL Franchises
Specialization + Scale + Distribution = 19.7% ROCE
Medanta’s business model is deceptively simple: build super-specialty hospitals in Tier-1 cities, focus on high-acuity treatments (cardiac, oncology, neurosciences, liver transplants, orthopedics), deploy experienced doctors, achieve high occupancy through brand and referral networks, and reinvest cash into new markets.
Revenue breakdown is diverse across specialties — no single department accounts for more than 22% of revenue. Cardio is the largest at 21%, followed by oncology (14.5%), neurosciences (11%), gastroenterology (12%), with the rest scattered across kidney/urology, ortho, liver transplant, and “others” (20.5%). This granularity is a moat; it means losing one specialty head doesn’t crater the hospital.
Bed capacity stands at 3,435 installed as of Sep 2025, spread across Gurugram (1,440), Lucknow (757), Patna (527), Indore (175), Ranchi (310), and Noida (226 operational, ramping to 550). Each hospital operates as a profit center, with different maturity profiles. Gurugram is a cash printer (₹1,440 beds, 23.9% EBITDA margin). Lucknow and Patna are scaling (30%+ margins). Noida is a loss-making dragon for now.
Working capital is a dream: occupancy of 62–64%, average patient stay of 3 days, and ARPOB (average revenue per occupied bed) of ₹67,361 — which is higher than most private hospital chains in North India. The payables cycle is 81 days, customer collections are 29 days, and inventory sits at 28 days. Net result: negative working capital of about 21 days. They finance the entire operation on payables float.
Beds (Operational)3,435Expanding to 5,000
ARPOB (Q3)₹67,361+10% YoY
Occupancy62.4%Improving
ALOS (Avg Stay)3.02 days7% YoY improvement
The Mix Shift Story: Management highlighted a structural shift in case-mix toward daycare oncology (radiation and medical oncology) from inpatient volumes. This is actually good — higher revenue per bed-day, faster throughput, better margins. But it’s masked by lower average length of stay (ALOS), which creates confusion in quarterly analysis. Smart investors are catching this.
💬 Have you or a family member received treatment at a Medanta hospital? If yes, did you feel the quality matched the premium pricing? Drop your experience in the comments.
04 — Financials Overview
Q3 FY26: Revenue Is Growing. Profit Is Struggling.
Result type: Quarterly Results | Q3 FY26 EPS: ₹3.54 | Annualised EPS (Q3×4): ₹14.16 | FY25 Full-Year EPS: ₹17.92
| Metric (₹ Cr) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue | 1,121 | 943 | 1,099 | +18.8% | +2.0% |
| EBITDA (incl. Noida) | 494 | 638 | 581 | -22.5% | -15.0% |
| EBITDA Margin % | 44% | 68% | 53% | -2,400 bps | -900 bps |
| PAT (reported) | 95 | 143 | 158 | -33.6% | -39.9% |
| EPS (₹) | 3.54 | 5.32 | 5.89 | -33.5% | -39.9% |
The Noida Elephant: EBITDA (including Noida) fell 22.5% YoY because Noida recorded an EBITDA loss of ₹320 crore in Q3 alone. Excluding Noida, EBITDA was actually ₹2,814 crore (+11% YoY), and margin was 25.4% — still healthy but pressured by staff costs and maintenance expenses. Also, reported PAT includes a ₹366-crore one-time statutory item from labour code implementation, which is non-recurring. Adjust for this, and adjusted PAT would’ve been ₹1,224 crore, or ₹45.6 per share. The narrative changes entirely once you remove the noise.
Per Concall (Feb 2026): Management signaled that Q3 “may have been” the peak loss quarter for Noida, citing improved run-rates in Dec 2025 onwards and payor (insurance) onboarding underway. But they provided no explicit guidance. This is the wildcard for 2026 earnings.
05 — Valuation: Fair Value Range
Paying 51.7x P/E for 5% Growth. Is This Magic or Mania?
Join 10,000+ investors who read this every week.
